Oxford BioMedica PLC (OXBDF)

[georgejjl]

Very interesting patent

Other large, protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, cMet, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, beta-Catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, alpha-fetoprotein, beta-HCG, BCA225, BTAA, CA 125, CA 15-3\CA 27.29\BCAA, CA 195, CA 242, CA-50, CAM43, CD68\P1, CO-029, FGF-5, G250, Ga733\EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB/70K, NY-CO-1, RCAS1, SDCCAG16, TA-90\Mac-2 binding protein\cyclophilin C-associated protein, TAAL6, TAG72, TLP, and TPS.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10040846.PN.&OS=PN/10040846&RS=PN/10040846

United States Patent 10,040,846
Frigault , et al. August 7, 2018
Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer

Abstract
The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.

Inventors: Frigault; Matthew J. (Philadelphia, PA), Zhao; Yangbing (Cherry Hill, NJ), Scholler; John (Narberth, PA), June; Carl H. (Merion Station, PA)
Applicant:
Name City State Country Type

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Philadelphia
PA
US
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Family ID: 49006240
Appl. No.: 14/375,015
Filed: February 22, 2013
PCT Filed: February 22, 2013
PCT No.: PCT/US2013/027337
371(c)(1),(2),(4) Date: July 28, 2014
PCT Pub. No.: WO2013/126712
PCT Pub. Date: August 29, 2013

Good luck and GOD bless,

George